TLC Biopharmaceuticals has failed to overturn a decision by the committee for human medicinal products within the European Medicines Agency to recommend refusing granting a marketing authorization for the firm’s hybrid application for a liposome-encapsulated doxorubicin solution, Doxolipad.
Breast and ovarian cancer treatment Doxolipad was intended to be similar to the Adriamycin reference brand, but with the active...





